Literature DB >> 1748682

Early induction of ribonucleotide reductase gene expression by transforming growth factor beta 1 in malignant H-ras transformed cell lines.

R A Hurta1, S K Samuel, A H Greenberg, J A Wright.   

Abstract

Previous investigations have indicated that the suppression of proliferation by transforming growth factor (TGF) beta 1 is often lost upon cellular transformation, and that proliferation of some tumors is stimulated by TGF-beta. The present study provides the first observation of a link between TGF-beta 1 regulation of this process and alterations in the expression of ribonucleotide reductase, a highly controlled rate-limiting step in DNA synthesis. A series of radiation and T24-H-ras-transformed mouse 10T1/2 cell lines exhibiting increasing malignant potential was evaluated for TGF-beta 1 induced alterations in ribonucleotide reductase M1 and M2 gene expression. Early increases in M1 and/or M2 message and protein levels were observed only in malignant cell lines. The TGF-beta 1 induced changes in M1 and/or M2 gene expression occurred prior to any detectable changes in the rates of DNA synthesis, supporting the novel concept that ribonucleotide reductase gene expression can be elevated by TGF-beta 1 without altering the proportion of cells in S phase. T24-H-ras-transformed 10T1/2 cells were transfected with a plasmid containing the coding region of TGF-beta 1 under the control of a zinc-sensitive metallothionein promoter. When these cells were cultured in the presence of zinc, a large induction of TGF-beta 1 message was observed within 1 h. Both M1 and M2 genes were also induced, with increased mRNA levels appearing 2 h after zinc treatment, or 1 h after TGF-beta 1 message levels were clearly elevated. In total, the data suggests a mechanism of autocrine stimulation of malignant cells by TGF-beta 1, in which early alterations in the regulation of ribonucleotide reductase may play an important role.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748682

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Defining a novel ribonucleotide reductase r1 mRNA cis element that binds to an unique cytoplasmic trans-acting protein.

Authors:  F Y Chen; F M Amara; J A Wright
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

2.  The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments.

Authors:  H Fan; A Huang; C Villegas; J A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  A novel transforming growth factor-beta 1 responsive cytoplasmic trans-acting factor binds selectively to the 3'-untranslated region of mammalian ribonucleotide reductase R2 mRNA: role in message stability.

Authors:  F M Amara; F Y Chen; J A Wright
Journal:  Nucleic Acids Res       Date:  1993-10-11       Impact factor: 16.971

4.  Phorbol ester tumour promoter mediated altered expression and regulation of matrix metalloproteinase-2 in a H-ras transformed cell line capable of benign tumour formation.

Authors:  O Yeung; R A Hurta
Journal:  Mol Cell Biochem       Date:  2001-04       Impact factor: 3.396

5.  Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.

Authors:  H Fan; C Villegas; J A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.

Authors:  Ai-Guo Lu; Hao Feng; Pu-Xiong-Zhi Wang; Ding-Pei Han; Xue-Hua Chen; Min-Hua Zheng
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

7.  Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.

Authors:  R A Jensen; D L Page; J T Holt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Authors:  Stephen I Shibata; James H Doroshow; Paul Frankel; Timothy W Synold; Yun Yen; David R Gandara; Heinz-Josef Lenz; Warren A Chow; Lucille A Leong; Dean Lim; Kim A Margolin; Robert J Morgan; George Somlo; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-26       Impact factor: 3.333

9.  Regulation of mammalian ribonucleotide reductase R1 mRNA stability is mediated by a ribonucleotide reductase R1 mRNA 3'-untranslated region cis-trans interaction through a protein kinase C-controlled pathway.

Authors:  F Y Chen; F M Amara; J A Wright
Journal:  Biochem J       Date:  1994-08-15       Impact factor: 3.857

10.  Defining a novel cis element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA: role in transforming growth factor-beta 1 induced mRNA stabilization.

Authors:  F M Amara; F Y Chen; J A Wright
Journal:  Nucleic Acids Res       Date:  1995-05-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.